Advertisement

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Jul

23

Today In Oncology

AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms

Multiple Myeloma Studies Highlight Advances Across the Field

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?

Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer

Advertisement

© 2026 HSP News Service, L.L.C.